Haemato-oncology
The molecular haemato-oncology service provides a molecular diagnostic, prognostic and treatment monitoring service for malignant haematological disorders. The laboratory works closely with the UCLH SIHMDS and other specialist units within the hospitals we provide a service to.
The laboratory offers:
- A comprehensive molecular work up for new acute leukaemia diagnoses.
- A comprehensive molecular work-up for chronic myeloproliferative disorders.
- Assessment of B and T cell clonality as well as MYD88 status for lymphomas.
- Monitoring of treatment efficacy in CML and Philadelphia positive ALL (qBCR-ABL).
- Assessment of IgVH mutation status in CLL.
We are always looking to expand our test repertoire in response to clinical demand.
Samples
- EDTA blood samples, which should be transported to the laboratory at ambient temperature.
- EDTA bone marrow samples, which should be transported to the laboratory at ambient temperature.
- FFPE tissue samples – please provide a minimum of five curls with a thickness of 5–10 microns each.
- Extracted DNA.
- Cerebrospinal fluid, pleural fluid, ascitic fluid and other aspirated body fluids.
Factors that significantly affect the performance of the examination or interpretation of results:
- Clotted samples
- Aged Samples (>48 hours
- Haemolysed samples
Note that samples for qBCR-ABL must arrive at the laboratory within 72 hours of having been taken. Samples received that are more than 72 hours old cannot be processed.
Reporting times
FLT3 and urgent Q30 leukaemia multiplex results will be reported within 48 hours of arriving in the laboratory. All other tests will be reported within 14 calendar days with the exception of IgVH mutation analysis which will be reported within 28 calendar days.
Requesting additional tests
Additional tests can be requested at any time via UCLH/SIHMDS HiLIS or by emailing the lab directly via molecular.haemonc@hslpathology.com.